



THE AGA KHAN UNIVERSITY

eCommons@AKU

Section of Gastroenterology

Department of Medicine

April 2008

Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection

Amna Subhan Butt

Aga Khan University, amna.subhan@aku.edu

Wasim Jafri

Aga Khan University, wasim.jafri@aku.edu

Khalid Mumtaz

Aga Khan University, khalid.mumtaz@aku.edu

Saeed Hamid

Aga Khan University, saeed.hamid@aku.edu

Shahab Abid

Aga Khan University, shahab.abid@aku.edu

Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol



Part of the [Gastroenterology Commons](#)

Recommended Citation

Butt, A., Jafri, W., Mumtaz, K., Hamid, S., Abid, S., Shah, S., Jafri, N., Yakoob, j., Ahmad, Z. (2008). Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection. *Gastroenterology*, 134(4), A-832-A-832.

Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/146

Authors

Amna Subhan Butt, Wasim Jafri, Khalid Mumtaz, Saeed Hamid, Shahab Abid, Syed H Shah, Nida Jafri, Javed Yakoob, and Zubair Ahmad

Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome with Plasma Exchange Improves Tolerability and Response to Interferon-Based Therapy

Todd Frederick, Jamie Zagorski, Robert G. Gish, Jan C. Hofmann

Introduction: Treatment of severe mixed cryoglobulinemic syndrome (MCS) associated with hepatitis C with interferon/ribavirin (IFN/RBV) is often difficult due to renal dysfunction, vasculitis, and neuropathy. **Methods:** We reviewed the medical records of 20 patients (pts) who were diagnosed with severe hepatitis C associated MCS and received interferon-based therapy and/or plasma exchange (PE). The mean age of pts was 54 years (46-63 years old) and 8 pts (40%) were male. 16 pts (80%) had HCV genotype 1A or 1B. 13 pts (65%) had elevated HCV RNA (>400,000 IU/ml) and 11 pts (55%) had cirrhosis or advanced fibrosis. **Clinical Presentation:** 17 pts (85%) presented with renal disease. 12 pts (60%) had chronic renal insufficiency, and 5 pts (25%) presented with acute renal failure requiring hemodialysis (HD). 17 pts (85%) had elevated 24-hour urine protein; 13 pts had nephrotic range proteinuria. 13 pts (65%) presented with active vasculitic skin lesions. 7 pts (35%) had peripheral neuropathy. 1 pt had severe CNS and pulmonary vasculitis. **Treatment:** Of 20 pts who received PE treatment, 16 pts (80%) were candidates to start (or reinstitute) IFN/RBV therapy (intent-to-treat [ITT] group). 11 of these pts successfully started Peg 2a/b IFN therapy, and 10 pts started RBV. 4 pts (20%) were not IFN/RBV candidates because of prior SVR or IFN/RBV failure. The mean number of inpatient PE treatments (txs) was 8.6 (5-12 txs). 8 pts (40%) received cyclophosphamide; 5 pts (25%) received rituximab (4-6 doses). 6 pts (30%) required chronic PE txs (2-8X/month). **Results:** 18 pts (90%) experienced clinical improvement after initial course of intensive PE therapy. Of 13 pts with nephrotic range proteinuria, 9 pts (69%) had significant decline in urinary protein. 3 of 5 pts (60%) on HD were able to stop dialysis. 12 pts (92%) demonstrated significant improvement in vasculitic skin lesions. 5 pts (71%) had slight improvement in peripheral neuropathy. Of 11 pts who received IFN/RBV post-PE (ITT success), 3 pts had SVR, 3 pts were NR, 4 pts had ongoing treatment (2 pts are HCV RNA neg., 2 are HCV RNA pos.), and 1 pt died but had EVR. The pts with SVR had marked improvement in MCS symptoms, whereas the NR pts all required chronic PE for refractory disease. Of 5 pts who did not receive IFN/RBV post-PE (ITT failure), 3 pts died (2 of complications of MCS) before starting IFN/RBV, 1 pt underwent transplantation, and 1 pt was not clinically stable for antiviral therapy. **Conclusion:** Treatment of hepatitis C associated severe mixed cryoglobulinemic syndrome with plasma exchange appears to improve tolerability and response to interferon-based therapy.

W1013

Feasibility of Interferon-Beta Induction By Twice-Daily Administration Prior to the Standard Combination Therapy Using Pegylated Interferon-Alpha-2b Plus Ribavirin

Toshiya Nakatani, Eri Satani, Shinya Takeyama, Sanae Murata, Shinsaku Nagamatsu, Koji Hashimoto, Hideki Matsuo, Eiryo Kikuchi

Aims: It has been reported that longer treatment with combination therapy using pegylated interferon (IFN)-alpha-2b plus ribavirin (RIB) for patients infected with hepatitis C virus (HCV) leads to more effective viral eradication. However, in Japan where treatment period is limited, the achievement of early viral clearance should be necessary. We already reported the effectiveness of IFN-beta induction prior to the standard 48-week combination therapy in achieving early viral response (EVR). In this study, it is evaluated whether IFN-beta induction is also effective in achieving sustained viral response (SVR). **Methods:** Sixty-two patients chronically infected with genotype 1b HCV were divided into 2 groups. Forty-two patients underwent standard 48-week combination therapy using 1.5µg/kg of pegylated IFN-alpha-2b plus RIB (600-1000 mg/day depending on body weight) (group1). Twenty patients received 3MU IFN-beta twice-daily for 2 weeks, followed by the standard combination therapy described above (group2). HCV quantity as well as its reduction profile such as HCV negativity and rate of 2-log decrease was assessed at the certain time point. Serum HCV-RNA was quantified using the Amplicor HCV monitor assay (SRL, Tokyo, Japan). EVR defined as HCV-RNA negative at weeks 12 in the 48-week therapeutic period tends to be referred to as one of the predictive landmarks for the subsequent SVR. We evaluated the effectiveness of IFN-beta induction by assessing EVR as well as SVR. **Results:** HCV quantity of each patient was more than 100 KIU/mL, meaning the high baseline viral load. Gender, age, platelet and ALT at baseline did not differ significantly between 2 groups. Serum HCV-RNA (KIU/mL) at baseline, weeks 2, 4, 8, 12, 16, 24 and 48 was 2248±1593/3197±1716 (P<0.05), 237±257/52±107 (P<0.05), 157±199/56±147, 107±176/16±59 (P<0.05), 79±155/0.2±0.3 (P<0.05), 69±148/14±58 (P<0.05) and 40±122/0±0 in group1 and group2, respectively. HCV negativity at weeks 2, 4, 8, 12, 20 and 28 was 0%/0%, 2.5%/15.8%, 17.9%/33.3%, 30.8%/87.5% (EVR; P<0.05), 44.1%/87.5% (P<0.05) and 63.3%/100% (P<0.05) in group1 and group2, respectively. SVR rate was 87.5%/47.9% (P<0.05) in group1 and group2, respectively. In the multivariate analysis, the factor of 'IFN-beta induction' was significantly and independently associated with EVR, and that of 'EVR achievement' was associated with SVR. **Conclusion:** When the length of combination therapy using pegylated IFN-alpha-2b plus RIB is limited to 48 weeks, IFN-beta induction may be feasible in achieving SVR throughout successful achievement of EVR.



W1014

Treatment After Liver Biopsy in Patients with Hepatitis C Virus (HCV) and HIV Co-Infection

Kavitha Gopal, Pauline Suwandhi, Arkady Broder, Henry C. Bodenheimer, Albert D. Min

Highly active antiretroviral therapy for HIV infection has decreased HIV-related mortality. However, due to accelerated progression of liver fibrosis and decompensation in HCV / HIV co-infected patients, the incidence of liver-related mortality has risen significantly. The aim of our study was to evaluate the number of liver biopsies in HCV / HIV co-infected patients and the influence on treatment decision. **Method:** We reviewed charts of patients with HCV / HIV co-infection who had a liver biopsy from 1/1998 to 10/2007, who have been followed

at our medical center. **Results:** Among the 238 patients with HCV / HIV co-infection seen during this study period, 152 (64%) had liver biopsy. Patients were predominantly male (116; 77%), and mean age at biopsy was 47.8 years (range 31-66). Majority of the patients were infected with genotype 1 (123; 81%). History of intravenous drug use and heavy alcohol consumption were documented in 104 (68%) and 32 (21%) patients, respectively. Fifty-three (35%), 82 (54%) and 13 (9%) patients had stage 0-1, 2-3, and 4 fibrosis, respectively. Stage was indeterminate in 3 (2%) patients. The number of liver biopsies and the rate of subsequent HCV treatment are shown in the figures 1 and 2. Fifty-seven of 152 (38%) patients were started on HCV treatment. Common reasons for not starting treatment after liver biopsy were patients lost to follow up in 26 (27%), minimal liver disease on biopsy in 20 (21%) and patients refusal in 17 (18%). **Conclusions:** The number of co-infected patients evaluated for treatment with a liver biopsy has decreased over past few years possibly due to a low threshold to start treatment in the co-infected patient. Low post-biopsy treatment rates with 21% of patients showing favorable histology, suggests that liver biopsy remains a useful tool in directing management in selected HIV / HCV co-infected patients.



W1015

Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection

Amna Subhan, Wasim Jafri, Khalid Mumtaz, Saeed S. Hamid, Shahab Abid, Hasnain Shah, Nida Jafri, Javed Yakoob, Zubair Ahmed

BACK GROUND: Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat and data on the outcome of treatment for this patient group is limited. **AIMS:** To study sustained virologic response (SVR) & its predictive factors in patients with compensated cirrhosis due to hepatitis C, treated with pegylated interferon & ribavirin. **METHODS:** Data of patients with compensated cirrhosis due to HCV genotype 3 with positive HCV RNA PCR was collected from our Gastroenterology clinic database during 2004 to 2006. Cirrhosis was diagnosed either by liver biopsy or on biochemical testing with ultrasound of abdomen. Primary end point of treatment was SVR. Treatment was terminated or modified in case of hepatic decompensation or if hemoglobin dropped to < 7.0 gm/dl, absolute neutrophil count (ANC) <1000 x10E 9, platelets <50,000/cmm. We also evaluated the predictors of outcomes of SVR. **RESULTS:** Out of 66 patients, 32(48.5%) were male. Mean age was 46± 10. 34/66 (51.5%) patients were non-naive. There were 61(92.4%) patients with Child's A cirrhosis followed by 5(7.6%) with child B. 33 (50%) patients received pegylated interferon alfa-2a (180mcg/wk) with ribavirin and 33(50%) received pegylated interferon alfa 2b (1-1.5mcg/kg/week) along with ribavirin. There were 46 (67.7%) patients who received treatment for 6 months and other 15 (22.7%) for 12 months, as they were unable to achieve EVR at 3 months and/or clear the virus at 6 months. EVR was achieved in 43(65.1%), and ETR in 49(74.24%); overall SVR was achieved in 38 (57.6%) patients. Factors predictive of SVR were age <35 years (p=0.01), treatment naïve status (p=0.04), EVR (p<0.01). Five patients were unable to complete the treatment due to side effects or cytopenias not responding to erythropoietin and/or G-CSF therapy. **Conclusions:** Treatment of HCV genotype 3 patients with compensated cirrhosis with pegylated interferon and ribavirin is effective and tolerable though supportive treatment with erythropoietin and G-CSF required in some cases. **Keywords:** hepatitis C, pegylated interferon, compensated cirrhosis

W1016

Efficacy and Safety of Erythropoietin-Alfa On Naïve Patients with Chronic Hepatitis C and Genotype 1 Receiving Combination Therapy with Pegylated Interferon-Alfa 2b and Ribavirin

Dagmary Purcell, Doris H. Toro

Background: Treatment of hepatitis C virus (HCV) infection with peg-interferon and ribavirin results in sustained viral response (SVR) in 42-46% of the patients with genotype 1. Weight based ribavirin in these subset of patients has been shown to increase the SVR. Erythropoietin